Rhenium N-heterocyclic carbene complexes block growth of aggressive cancers by inhibiting FGFR- and SRC-mediated signalling

BACKGROUND: Platinum-based anticancer drugs have been at the frontline of cancer therapy for the last 40 years, and are used in more than half of all treatments for different cancer types. However, they are not universally effective, and patients often suffer severe side effects because of their lac...

Descripción completa

Detalles Bibliográficos
Autores principales: Domenichini, Alice, Casari, Ilaria, Simpson, Peter V., Desai, Nima Maheshkumar, Chen, Lingfeng, Dustin, Christopher, Edmands, Jeanne S., van der Vliet, Albert, Mohammadi, Moosa, Massi, Massimiliano, Falasca, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720599/
https://www.ncbi.nlm.nih.gov/pubmed/33287862
http://dx.doi.org/10.1186/s13046-020-01777-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720599/
https://www.ncbi.nlm.nih.gov/pubmed/33287862
http://dx.doi.org/10.1186/s13046-020-01777-7

Ejemplares similares